Tectonic Therapeutic, Inc. (TECX) – What Are Researchers Thinking About This Stock?Defense World · 4 days ago
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)GlobeNewsWire · Sep 29, 2026
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to AnalystsDefense World · Sep 26, 2026
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare ConferenceGlobeNewsWire · Sep 3, 2026
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull CaseSeeking Alpha · Sep 2, 2026
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire · Aug 6, 2026Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.35 | -$1.18 | Beat |
| May 7, 2026 | -$1.16 | -$1.34 | Miss |
| Feb 26, 2026 | -$1.11 | -$1.03 | Beat |
| Nov 6, 2025 | -$1.05 | -$1.02 | Beat |
| Aug 7, 2025 | -$0.98 | -$1.07 | Miss |
| May 8, 2025 | -$1.10 | -$0.93 | Beat |